Sanders, Cummings Demand PTC Therapeutics Chief Peltz Spell Out Price For Controversial DMD Drug

It’s time for Stuart Peltz to take the Congressional hot seat on drug pricing.

The CEO of PTC Therapeutics acquired Marathon’s steroid deflazacort for $140 million up front a few days ago with an eye to sell it to a small population of Duchenne muscular dystrophy patients. And that comes with as much of a glaring spotlight as Senator Bernie Sanders and Rep. Elijah Cummings can bring to it.

Back to news